Anti-OTUB2 antibody produced in rabbit，100UL，HPA002329-100UL，Sigma

General description

OTU deubiquitinase, ubiquitin aldehyde binding 2 (OTUB2) is a 29kDa, cysteine protease belonging to the OTU (ovarian tumour) superfamily of proteins. It has two isoforms namely otubain 1 and otubain 2. Both the otubains consist of OTU domain with an active cysteine protease site. It has short carboxy-terminal extension which makes it different from OTUB1. It is involved in mediating lymphocyte antigen responsiveness.

Immunogen

OTU deubiquitinase, ubiquitin aldehyde binding 2

Application

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

Biochem/physiol Actions

OTUB2 (OTU deubiquitinase, ubiquitin aldehyde binding 2) plays an important role in protein degradation machinery and in specific ubiquitin dependent pathways. It forms a complex with Uba (Ub-associated domains). Its activity is inhibited by mutation of the active site cysteine (C51S). It contains conserved cysteine, histidine and aspartate residues that help in the putative catalytic cysteine protease activity. It also consists of a nuclear localization signals (NLS) and a consensus LxxLL motif that mediates the binding of transcriptional co-activators to nuclear receptors.

Features and Benefits

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Physical form

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Other Notes

Corresponding Antigen APREST70530

Legal Information

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany